2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155733
    AChE/Aβ-IN-1 98%
    AChE/Aβ-IN-1 (compound 32) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with an IC50 of 86 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC50 of 3.876 μM. AChE/Aβ-IN-1 also inhibits Aβ aggregation and shows good blood-brain barrier permeability and neuroprotection. AChE/Aβ-IN-1 improves cognitive and spatial memory impairment in rats model.
    AChE/Aβ-IN-1
  • HY-155735
    AChE/Aβ-IN-2 98%
    AChE/Aβ-IN-2 (compound 33) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with IC50 of 135 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC50 of 5.054 μM. AChE/Aβ-IN-2 also inhibits Aβ aggregation and shows good blood-brain barrier permeability. AChE/Aβ-IN-2 improves cognitive and spatial memory impairment in rats model.
    AChE/Aβ-IN-2
  • HY-155741
    CB2 PET Radioligand 1 98%
    CB2 PET Radioligand 1 (compound [18F]9) is a PET Radioligand targeting to hCB2 (Ki=7.7 nM). CB2 PET Radioligand 1 is prepared with Cu-mediated 18F-fluorination. CB2 PET Radioligand 1 shows high brain uptake in a murine model of neuroinflammation.
    CB2 PET Radioligand 1
  • HY-155749
    AChE-IN-36 2978753-66-9 98%
    AChE-IN-36 (compound A4) is anacetylcholinesterase inhibitorswith an IC50 of 0.04 μM. AChE-IN-36 effects ROS levels and gene expression of NRF2.
    AChE-IN-36
  • HY-155750
    AChE-IN-37 2978753-64-7 98%
    AChE-IN-37 (compound A2) is anacetylcholinesterase inhibitorswith an IC50 of 0.23 μM. AChE-IN-37 effects ROS levels and gene expression of NRF2.
    AChE-IN-37
  • HY-155762
    Anti-neuroinflammation agent 1 2968412-77-1 98%
    Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype.
    Anti-neuroinflammation agent 1
  • HY-155822
    TZ3O 98.17%
    TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research.
    TZ3O
  • HY-155823
    TZ4M 98%
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model.
    TZ4M
  • HY-155958
    Casein kinase 1δ-IN-9 854355-54-7 ≥98.0%
    Casein kinase 1δ-IN-9 (compound 737) is a potent casein kinase 1δ (CK1δ/CK15) inhibitor. Casein kinase 1δ-IN-9 can be used for the research of neurodegenerative disorders such as Alzheimer's disease.
    Casein kinase 1δ-IN-9
  • HY-155988
    Sirtuin modulator 6 476633-98-4 98%
    Sirtuin modulator 6 (compound 262) increases the lifespan of a cell. Sirtuin modulator 6 can be used for study of diabetes, obesity, neurodegenerative diseases, cardiovascular disease, and so an extracted from patent WO2009064913A1.
    Sirtuin modulator 6
  • HY-155989
    GSK3-IN-4 748145-19-9 98%
    GSK3-IN-4 (compound 0715) is a potent GSK3 inhibitor. GSK3-IN-4 can be used for psychiatric disorder research.
    GSK3-IN-4
  • HY-156011
    PSEN1-IN-1 98%
    PSEN1-IN-1 (Compound (+)-13b) is a PSEN1 inhibitor. PSEN1-IN-1 inhibits PSEN1-APH1A and PSEN1-APH1B complex with IC50s of 19 and 5.5 nM. PSEN1-IN-1 can be used for Alzheimer's disease research.
    PSEN1-IN-1
  • HY-156012
    PSEN1-IN-2 98%
    PSEN1-IN-2 (Compound 13K) is a PSEN1 inhibitor. PSEN1-IN-2 inhibits PSEN1-APH1A and PSEN1-APH1B complex with IC50s of 6.9 and 2.4 nM. PSEN1-IN-2 can be used for Alzheimer's disease research.
    PSEN1-IN-2
  • HY-156017
    5-HT6R antagonist 1 98%
    5-HT6R antagonist 1 (Comopund 8) is a 5-HT6R antagonist (Ki: 5 nM). 5-HT6R antagonist 1 inhibits platelet aggregation. 5-HT6R antagonist 1 has excellent metabolic stability. 5-HT6R antagonist 1 reverses MK-801 (HY-15084B)-induced memory impairments in rats. 5-HT6R antagonist 1 can be used for Alzheimer's disease (AD) research.
    5-HT6R antagonist 1
  • HY-156030
    AChE-IN-40 98%
    AChE-IN-40 (Compound 5C) is an AChE inhibitor (IC50: 120 nM). AChE-IN-40 can be used for research of Alzheimer's disease.
    AChE-IN-40
  • HY-156031
    BChE-IN-19 98%
    BChE-IN-19 (Compound 7b) is a para-substituted derivative of indone (7b) with inhibitory activity of butyryl cholinesterase (BChE) (IC50=0.04 μM). BChE-IN-19 improves cholinergic scheduling in the nervous system. BChE-IN-19 can be used against Alzheimer's disease.
    BChE-IN-19
  • HY-156032
    PIMPC 2250244-44-9 98%
    PIMPC is a compound with antioxidant and metal-chelating properties. PIMPC is a novel inhibitor of glycogen synthase kinase 3 (GSK-3). PIMPC has potential anti-Alzheimer's disease effect.
    PIMPC
  • HY-156054
    N-Hydroxy riluzole 179070-90-7 98%
    N-Hydroxy riluzole is a metabolite of the antiglutamatergic agent Riluzole (HY-B0211).
    N-Hydroxy riluzole
  • HY-156061
    NAP-1 131721-28-3 98%
    NAP-1 is a compound with agent that can suppress or relieve pain. effects. NAP-1 enhances the inhibitory current by binding to a specific site of GABAaR, resulting in a narcotic effect. NAP-1 can be used in research to develop clinical agent that can suppress or relieve pain.
    NAP-1
  • HY-156079
    Antidepressant agent 5 1071049-42-7 98%
    Antidepressant agent 5 (Compound 3i) is a 7-substituted tetrahydroisoquinolines derivatives. Antidepressant agent 5 exhibits almost equal antidepressant activity compared with magnoflorine. ntidepressant agent 5 can be used for depressive disorder research.
    Antidepressant agent 5
Cat. No. Product Name / Synonyms Application Reactivity